USA – FDA warns of potential drug interaction with remdesivir

Hours after revoking its emergency use authorization (EUA) for hydroxychloroquine and chloroquine to treat coronavirus disease (COVID-19), the US Food and Drug Administration (FDA) is now warning that the drugs could interact with Gilead Sciences’ remdesivir, potentially reducing its antiviral activity.
 
Remdesivir, also authorized under an EUA, is now the only drug with emergency authorization to treat COVID-19 in the US. (RELATED: FDA revokes EUA for hydroxychloroquine, chloroquineRegulatory Focus 15 June 2020; FDA authorizes Gilead’s remdesivir for emergency useRegulatory Focus 1 May 2020)…